Table 3. Follow-up characteristics of the patients.
| Characteristics | Total patients (N = 69) | LRE (N = 27) | Non-LRE (N = 42) | P |
| Age (years) | 5.4±3.7 | 5.3±3.2 | 5.4±3.9 | NS |
| AST (IU/L) | 173.6±142.5 | 221.9±107.5 | 124.3±173.8 | 0.032 |
| ALT (IU/L) | 164.7±102.1 | 177.9±105.8 | 103.9±147.1 | 0.059 |
| Albumin (g/dL) | 3.45±0.71 | 3.33±0.50 | 3.86±0.63 | 0.003 |
| Total bilirubin (mg/dL) | 4.79±5.24 | 8.91±5.32 | 1.47±2.64 | <0.001 |
| Direct bilirubin (mg/dL) | 4.05±4.59 | 7.29±4.39 | 1.05±2.21 | <0.001 |
| GGT (IU/L) | 500.1±312.2 | 609.6±596.4 | 240.0±389.6 | 0.006 |
| ALP (IU/L) | 557.8±358.6 | 609.2±510.5 | 427.5±429.9 | 0.162 |
| PT-INR | 1.167±0.477 | 1.643±1.011 | 1.148±0.443 | 0.01 |
| Platelet count (109/L) | 296.1±193.8 | 192.3±112.3 | 232.1±114.7 | 0.219 |
| Onset duration of LRE (months) | 32.5±29.4 | |||
| Modes of LRE | ||||
| Jaundice | 9/69 | 9/27 | 0/42 | |
| Ascites | 4/69 | 4/27 | 0/42 | |
| Variceal bleeding | 7/69 | 7/27 | 0/42 | |
| Liver related death | 9/69 | 9/27 | 0/42 |
LRE, liver related events; LSM, liver stiffness measurement; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transpeptidase; ALP, alkaline phosphatase; PT-INR, prothrombin time-international normalized ratio.